SecBot SecBot
COURT-RULING ·Filed Aug 17, 2026

ALNY

ALNYLAM PHARMACEUTICALS, INC.
NEUTRAL
Impact 4/10
Horizonmonths Processed2mo ago CourtCourt Ruling · govinfo.gov
Court ruling (district)
Actionable Insight • Neutral

The court split the claim construction rulings, giving Alnylam wins on two key terms but rejecting its broader narrowing attempts. The case continues toward trial on infringement and validity, monitor for summary judgment motions and trial dates. ONPATTRO revenue is not immediately at risk, but a future adverse ruling could create royalty obligations or an injunction.

DirectionNeutral
Confidencemedium
Horizonmonths

ONPATTRO

● Neutral Named in this court ruling
Impact
Phase
Approved (marketed); Phase 3 (APOLLO-B) completed
Time to market
Already approved and marketed — FDA approval recorded 2018-08-10; no new indication approval pending in local FDA records.
Next catalyst
None dated

What to watchDo not position in ALNY for an ONPATTRO-specific catalyst, there isn't one on the horizon; treat ONPATTRO as a slowly amortizing cash-flow asset whose quarterly revenue lines (Q2 2026 10-Q filed 2026-07-30) are worth watching inside ALNY's earnings for the pace of patient transition to newer franchise drugs. ALNY's mean analyst target of ~$427.61 (observed 2026-07-31) implies the market values the pipeline, not this legacy product, so any trade thesis should hinge on the rest of the portfolio (e.g., cemdisiran) rather than ONPATTRO.

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$228.61
T+0 close · Aug 18, 2026 · via day close
Latest settled
−33.67%
T+60 · $151.64
Vs SPY
−31.63%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 18 $228.61entry
  2. T+1 · 3mo ago +6.12%α +5.91% · $242.61
  3. T+5 · 3mo ago +5.02%α +5.22% · $240.08
  4. T+20 · 2mo ago +4.70%α +6.45% · $239.36
  5. T+60 · 6d ago −33.67%α −31.63% · $151.64
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

A Markman claim construction ruling in a patent case brought by the University of Texas against Alnylam over its drug ONPATTRO. The court adopted constructions favorable to Alnylam on two key terms, defining 'liposome' narrowly as requiring an inner aqueous medium (excluding micelles) and ruling that the phospholipid component must contain no lysophosphatides, while rejecting Alnylam's proposed constructions on other terms. This is an interlocutory ruling that shifts the probability of eventual infringement liability but does not resolve the case, and the mixed outcome limits its immediate market impact.

Court Ruling Details

Ruling Date
Aug 17, 2026
Court
United States District Court for the District of Massachusetts
Court Level
District
Judge
Brian E. Murphy
Case Type
patent
Ruling Type
other
Outcome
PARTIAL: mixed ruling, some claims won/lost
Appeal Timeline
After final judgment, likely 1-2 years for Federal Circuit appeal
Precedent Risk
LOW

Key Facts

  • The court construed 'liposome' as 'a lipid vehicle having one or more lipid bilayers or aggregates surrounding an inner aqueous medium,' adopting Alnylam's proposed construction.
  • The court ruled that 'the phospholipid is not a lysophosphatidylcholine or lysophosphatidylethanolamine' means 'the phospholipid component contains no lysophosphatidylcholine or lysophosphatidylethanolamine,' also adopting Alnylam's construction.
  • The court rejected Alnylam's proposed constructions for 'a lipid component' and 'a phospholipid component,' instead adopting modified versions of the University's proposals.
  • The court declined to construe 'a neutral charge' and 'encapsulate the siRNA such that greater than 90% of the liposomes encapsulate siRNA,' finding they have plain and ordinary meaning.
  • The case concerns Alnylam's drug ONPATTRO, a commercial product, but no damages or injunction were awarded at this stage.
  • This is a Markman (claim construction) ruling, an interlocutory order that does not resolve infringement or validity.

Financial Impact

No damages or financial exposure quantified in the ruling. The case concerns ONPATTRO, a commercial RNAi therapeutic, but this is an early-stage claim construction ruling with no monetary award.

patent risklitigation exposure

Risk Factors

  • Case continues toward trial on infringement and validity, no resolution yet.
  • Adverse claim constructions on 'lipid component' and 'phospholipid component' leave room for plaintiff's infringement theory.
  • If Alnylam ultimately loses, ONPATTRO could face royalty obligations or an injunction.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
78% bullish (37 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 court opinion.

DocumentAccession Number
COURT-RULING Data (Synthetic)court-b0d498de6d-ALNY

Track record

15 reports on ALNY

Performance horizon

1 of 5 bullish or bearish reports moved the stock their way by T+5. Best: +26.35% at T+5 after the Oct 23, 2026 report. 1 of 5 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G Neutral 3/10 Entry $160.53 Now $159.73 −0.50% settles Nov 23
  2. Nov 13, 20263d ago SC 13G/A Neutral 2/10 Entry $165.50 Now $159.73 −3.49% settles Nov 23
  3. Nov 13, 20263d ago SC 13G/A Neutral 2/10 Entry $165.04 Now $159.73 −3.22% settles Nov 20
  4. Nov 12, 20264d ago Insider Cluster Neutral 2/10 Entry $165.04 Now $159.73 −3.22% settles Nov 20
  5. Nov 5, 202611d ago SC 13G/A Neutral 3/10 Entry $156.66 to $156.65 Now $159.73 +1.96% ▼ −0.01% −3.30% vs SPY
  6. Nov 5, 202611d ago 8-K Neutral 4/10 Entry $156.66 to $156.65 Now $159.73 +1.96% ▼ −0.01% −3.30% vs SPY
  7. Oct 30, 202617d ago SC 13G Neutral 3/10 Entry $165.00 to $155.94 Now $159.73 −3.19% ▼ −5.49% −2.79% vs SPY
  8. Oct 29, 202618d ago 8-K Bullish 6/10 Entry $174.00 to $156.66 Now $159.73 −8.20% ▼ −9.97% −5.24% vs SPY
  9. Oct 23, 202624d ago Institutional Cluster Bearish 4/10 Entry $224.03 to $165.00 Now $159.73 +28.70% ▲ +26.35% +25.79% vs SPY
  10. Aug 17, 202613w ago Court Ruling Neutral 4/10 Viewing Entry $228.61 to $240.08 Now $159.73 −30.13% ▲ +5.02% +5.22% vs SPY
Showing 10 of 15

US Market Status

Market Closed · Opens in 7h 14m

Subscribe to SecBot

Get Real-Time Court Ruling Intelligence

Market-moving court rulings analyzed within minutes. Patent verdicts, antitrust decisions, class certifications, and more, parsed and scored by AI.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
⚖ Court Ruling · govinfo.gov Report published Aug 19, 2026